Amgen Czech Republic made a net profit of CZK 37.8 mil with revenues of CZK 417 mil in 2017, up by 20% and down by 33.4%, respectively, compared to the previous year. This translates into a net margin of 9.06%.
On the operating level, EBITDA reached CZK 49.0 mil, up 26.3% compared to the previous year. Over the last five years, the company's EBITDA has risen 5.65% a year on average.
The company generated cash, defined by a sum of net profit and depreciation, of CZK 38.3 mil or 9.19% of sales. When investments are excluded, free cash flow reached CZK 60.0 mil, or 14.4% of sales in 2017.
In the last five years, the company generated free cash flow of CZK 180 mil. That compares to a cumulative net profit of CZK 174 mil in the same period.
You can see all the company’s data at Amgen Czech Republic profile, or you can download a report on the company in the report section.
Helgi Library 
